Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study

OBJECTIVE: To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: In a 48-week open-label prospective extension study to the PATH study, patients were initially started on 0.2 g/kg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurol Neuroimmunol Neuroinflamm
Autors principals: van Schaik, Ivo N., Mielke, Orell, Bril, Vera, van Geloven, Nan, Hartung, Hans-Peter, Lewis, Richard A., Sobue, Gen, Lawo, John-Philip, Praus, Michaela, Durn, Billie L., Cornblath, David R., Merkies, Ingemar S. J.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624149/
https://ncbi.nlm.nih.gov/pubmed/31355323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000590
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars